Cite
A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
MLA
Tariq, Bilal, et al. “A Phase 1, Open-Label, Randomized Drug–drug Interaction Study of Zanubrutinib with Moderate or Strong CYP3A Inhibitors in Patients with B-Cell Malignancies.” Leukemia & Lymphoma, vol. 64, no. 2, Feb. 2023, pp. 329–38. EBSCOhost, https://doi.org/10.1080/10428194.2022.2150820.
APA
Tariq, B., Ou, Y. C., Stern, J. C., Mundra, V., Wong Doo, N., Walker, P., Lewis, K. L., Lin, C., Novotny, W., Sahasranaman, S., & Opat, S. (2023). A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia & Lymphoma, 64(2), 329–338. https://doi.org/10.1080/10428194.2022.2150820
Chicago
Tariq, Bilal, Ying C. Ou, Jennifer C. Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L. Lewis, et al. 2023. “A Phase 1, Open-Label, Randomized Drug–drug Interaction Study of Zanubrutinib with Moderate or Strong CYP3A Inhibitors in Patients with B-Cell Malignancies.” Leukemia & Lymphoma 64 (2): 329–38. doi:10.1080/10428194.2022.2150820.